Dr Agarwal's Health Care Gets BUY Rating from Avendus Spark; ₹495 Target Price Signals 18% Upside

Eye Care Leader Attracts Bullish Research Call

Avendus Spark Institutional Equities has marked its entry into coverage of Dr Agarwal's Health Care [DRAGARWAL] with an optimistic outlook, assigning a 'buy' rating and a target price of ₹495 per share. This valuation implies approximately 18.3% upside potential from current levels, signaling the brokerage's confidence in the healthcare provider's growth trajectory.

Strategic Positioning in High-Growth Segment

The ophthalmology-focused healthcare company is well-positioned to capitalize on India's expanding eye care market, which is experiencing robust growth driven by increasing diagnostic awareness and rising disposable incomes. Avendus Spark's positive stance reflects optimism around Dr Agarwal's expansion strategy and operational momentum.

Growth Catalysts: Acquisitions and Surgical Expansion

According to the research initiation, the company's growth is expected to be fueled by two primary drivers. First, strategic acquisitions will help Dr Agarwal's expand its geographic footprint and enhance service capabilities across tier-1 and tier-2 cities. Second, rising surgical revenues from cataract surgeries, LASIK procedures, and other specialized treatments will contribute meaningfully to earnings growth.

The healthcare sector continues to attract institutional investor interest as India's middle class increasingly prioritizes health screenings and elective surgical procedures. Dr Agarwal's established brand presence and network of centers position it favorably within this favorable demand environment.

What Investors Should Note

While the 'buy' rating from Avendus Spark provides a positive research endorsement, potential investors should evaluate their own risk tolerance and investment horizon. The healthcare sector, though fundamentally sound, can be influenced by regulatory changes, competitive pressures, and macroeconomic factors affecting consumer spending.

This initiation of coverage underscores growing institutional recognition of Dr Agarwal's Health Care's potential in India's evolving healthcare landscape, particularly within the specialized eye care segment where the company maintains a leadership position.

Brokerage Details:

• Brokerage: Avendus Spark Institutional Equities
• Rating: BUY
• Target Price: ₹495
• Upside Potential: 18.3%

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Stock market investments are subject to market risks. Please consult your financial advisor before making any investment decisions. StockTips.in is not a SEBI-registered investment advisor.